...
首页> 外文期刊>The FEBS journal >An estrogen receptor l suppressor, microRNA-22, is downregulated in estrogen receptor l-positive human breast cancer cell lines and clinical samples
【24h】

An estrogen receptor l suppressor, microRNA-22, is downregulated in estrogen receptor l-positive human breast cancer cell lines and clinical samples

机译:雌激素受体l阳性的人乳腺癌细胞系和临床样品中的雌激素受体l抑制剂microRNA-22被下调

获取原文
获取原文并翻译 | 示例
           

摘要

Previous studies have suggested that microRNAs (miRNAs) may play important roles in tumorigenesis, but little is known about the functions of most miRNAs in cancer development. In the present study, we set up a cell-based screen using a luciferase reporter plasmid carrying the whole ~ 4.7 kb 3o-UTR of estrogen receptor l (ERl) mRNA cotransfected with a synthetic miRNA expression library to identify potential ERl-targeting miRNAs. Among all the miRNAs, miR-22 was found to repress robustly the luciferase signal in both HEK-293T and ERl-positive MCF-7 cells. Mutation of the target site was found to abrogate this repression effect of miR-22, whereas antagonism of endogenous miR-22 in MDA-MB-231 cells resulted in elevated reporter signals. We assessed the miR-22 expression patterns in five breast cancer cell lines and 23 clinical biopsies and revealed that there is a significant inverse association between the miR-22 levels and ERl protein expression. To evaluate the potential of miR-22 as a potential therapeutic intervention, we found that reduction of endogenous ERl protein levels and suppression of cancer cell growth could be achieved in MCF-7 cells by miR-22 overexpression in a way that can be recapitulated by the introduction of specific small interfering RNA against ERl. The phenomena can be rescued by the reintroduction of ERl. Taken together, our data indicate that miR-22 was frequently downregulated in ERl-positive human breast cancer cell lines and clinical samples. Direct involvement in the regulation of ERl may be one of the mechanisms through which miR-22 could play a pivotal role in the pathogenesis of breast cancer.
机译:先前的研究表明,microRNA(miRNA)可能在肿瘤发生中起重要作用,但对于大多数miRNA在癌症发展中的功能了解甚少。在本研究中,我们使用携带完整〜4.7 kb 3o-UTR的雌激素受体l(ER1)mRNA的荧光素酶报道质粒与合成的miRNA表达文库共转染的荧光素酶报告质粒,建立了基于细胞的筛选,以鉴定潜在的靶向ERl的miRNA。在所有miRNA中,发现miR-22在HEK-293T和ER1阳性MCF-7细胞中均能强烈抑制萤光素酶信号。发现靶位点的突变消除了miR-22的这种抑制作用,而MDA-MB-231细胞中内源性miR-22的拮抗作用导致报告基因信号升高。我们评估了五种乳腺癌细胞系和23种临床活检组织中的miR-22表达模式,并揭示了miR-22水平与ER1蛋白表达之间存在显着的负相关。为了评估miR-22作为潜在的治疗干预措施的潜力,我们发现通过miR-22的过量表达,MC​​F-7细胞可以降低内源性ER1蛋白水平并抑制癌细胞的生长,可以通过以下方法概括引入针对ER1的特异性小干扰RNA。可以通过重新引入ER1来挽救该现象。两者合计,我们的数据表明miR-22在ER1阳性的人乳腺癌细胞系和临床样品中经常被下调。直接参与ER1的调控可能是miR-22可能在乳腺癌发病机理中起关键作用的机制之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号